Journal Article
. 2020 Jan; 12(2):.
doi: 10.3390/cancers12020284.

Mechanism- and Immune Landscape-Based Ranking of Therapeutic Responsiveness of 22 Major Human Cancers to Next Generation Anti-CTLA-4 Antibodies

Peng Zhang 1 Xinxin Xiong 2 Christian Rolfo 3 Xuexiang Du 1 Yan Zhang 1 Han Yang 2 Alessandro Russo 3 Martin Devenport 4 Penghui Zhou 2 Yang Liu 1 Pan Zheng 1 
  • PMID: 31991588
  •     39 References
  •     3 citations


Background: CTLA-4 was the first immune checkpoint targeted for cancer therapy and the first target validated by the FDA (Food and Drug Administration) after approval of the anti-CTLA-4 antibody, Ipilimumab. However, clinical response rates to anti-CTLA-4 antibodies are lower while the rates of immunotherapy-related adverse events (irAE) are higher than with anti-PD-1 antibodies. As a result, the effort to target CTLA-4 for cancer immunotherapy has stagnated. To reinvigorate CTLA-4-targeted immunotherapy, we and others have reported that rather than blocking CTLA-4 interaction with its cognate targets, CD80 and CD86, anti-CTLA-4 antibodies achieve their therapeutic responses through selective depletion of regulatory T cells in the tumor microenvironment. Accordingly, we have developed a new generation of anti-CTLA-4 antibodies with reduced irAE and enhanced antibody-dependent cell-mediated cytotoxicity/phagocytosis (ADCC/ADCP). A major unresolved issue is how to select appropriate cancer types for future clinical development.

Methods: We generated a landscape of the immune tumor microenvironment from RNAseq and genomic data of 7279 independent cancer samples belonging to 22 cancer types from The Cancer Genomics Atlas (TCGA) database. Based primarily on genomic and RNAseq data from pre-treatment clinical samples of melanoma patients who were later identified as responders and nonresponders to the anti-CTLA-4 antibody Ipilimumab, we identified 5 ranking components of responsiveness to anti-CTLA-4, including CTLA-4 gene expression, ADCC potential, mutation burden, as well as gene enrichment and cellular composition that favor CTLA-4 responsiveness. The total ranking number was calculated by the sum of 5 independent partitioning values, each comprised of 1-3 components.

Results: Our analyses predict metastatic melanoma as the most responsive cancer, as expected. Surprisingly, non-small cell lung carcinoma (NSCLC) is predicted to be highly responsive to anti-CTLA-4 antibodies. Single-cell RNAseq analysis and flow cytometry of human NSCLC-infiltrating T cells supports the potential of anti-CTLA-4 antibodies to selectively deplete intratumoral Treg.

Conclusions: Our in silico and experimental analyses suggest that non-small cell lung carcinoma will likely respond to a new generation of anti-CTLA-4 monoclonal antibodies. Our approach provides an objective ranking of the sensitivity of human cancers to anti-CTLA-4 antibodies. The comprehensive ranking of major cancer types provides a roadmap for clinical development of the next generation of anti-CTLA-4 antibodies.

Keywords: ADCC/ADCP; Anti-CTLA-4 antibody; TCGA; immunotherapy responsiveness; irAE; lung cancer; treg.

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
Michele Maio, Arnaud Scherpereel, +15 authors, Hedy L Kindler.
Lancet Oncol, 2017 Jul 22; 18(9). PMID: 28729154
Highly Cited.
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies.
Yannick Bulliard, Rose Jolicoeur, +6 authors, Jennifer L Brogdon.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897982    Free PMC article.
Highly Cited.
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
Jeffrey Weber, Mario Mandala, +32 authors, CheckMate 238 Collaborators.
N Engl J Med, 2017 Sep 12; 377(19). PMID: 28891423
Highly Cited.
Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer.
George Plitas, Catherine Konopacki, +5 authors, Alexander Y Rudensky.
Immunity, 2016 Nov 17; 45(5). PMID: 27851913    Free PMC article.
Highly Cited.
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.
Alexander M M Eggermont, Vanna Chiarion-Sileni, +24 authors, Alessandro Testori.
N Engl J Med, 2016 Oct 09; 375(19). PMID: 27717298    Free PMC article.
Highly Cited.
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.
Aravind Subramanian, Pablo Tamayo, +8 authors, Jill P Mesirov.
Proc Natl Acad Sci U S A, 2005 Oct 04; 102(43). PMID: 16199517    Free PMC article.
Highly Cited.
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.
Tomasz M Beer, Eugene D Kwon, +20 authors, Winald Gerritsen.
J Clin Oncol, 2016 Dec 31; 35(1). PMID: 28034081
Highly Cited.
Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis.
Bin Shang, Yao Liu, Shu-juan Jiang, Yi Liu.
Sci Rep, 2015 Oct 16; 5. PMID: 26462617    Free PMC article.
Highly Cited. Systematic Review.
Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy.
Yan Zhang, Xuexiang Du, +9 authors, Yang Liu.
Cell Res, 2019 Jul 04; 29(8). PMID: 31267017    Free PMC article.
How Does an Anti-CTLA-4 Antibody Promote Cancer Immunity?
Yang Liu, Pan Zheng.
Trends Immunol, 2018 Dec 01; 39(12). PMID: 30497614    Free PMC article.
Melanoma drug wins US approval.
Heidi Ledford.
Nature, 2011 Apr 02; 471(7340). PMID: 21455150
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.
Christian U Blank, Elisa A Rozeman, +21 authors, Ton N Schumacher.
Nat Med, 2018 Oct 10; 24(11). PMID: 30297911
Highly Cited.
FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.
Wu Zhang, Michael Gordon, +10 authors, Heinz-Josef Lenz.
J Clin Oncol, 2007 Aug 21; 25(24). PMID: 17704420
Highly Cited.
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.
Xuexiang Du, Fei Tang, +14 authors, Yang Liu.
Cell Res, 2018 Feb 24; 28(4). PMID: 29472691    Free PMC article.
Highly Cited.
Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions.
Nobuyoshi Hiraoka, Kaoru Onozato, Tomoo Kosuge, Setsuo Hirohashi.
Clin Cancer Res, 2006 Sep 27; 12(18). PMID: 17000676
Highly Cited.
Genetic basis for clinical response to CTLA-4 blockade in melanoma.
Alexandra Snyder, Vladimir Makarov, +18 authors, Timothy A Chan.
N Engl J Med, 2014 Nov 20; 371(23). PMID: 25409260    Free PMC article.
Highly Cited.
Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies.
Kenneth D Lute, Kenneth F May, +8 authors, Yang Liu.
Blood, 2005 Jul 23; 106(9). PMID: 16037385    Free PMC article.
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.
Eliezer M Van Allen, Diana Miao, +19 authors, Levi A Garraway.
Science, 2015 Sep 12; 350(6257). PMID: 26359337    Free PMC article.
Highly Cited.
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
Antoni Ribas, Richard Kefford, +21 authors, Axel Hauschild.
J Clin Oncol, 2013 Jan 09; 31(5). PMID: 23295794    Free PMC article.
Highly Cited.
Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse.
Gaynor J Bates, Stephen B Fox, +4 authors, Alison H Banham.
J Clin Oncol, 2006 Dec 01; 24(34). PMID: 17135638
Highly Cited.
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.
Mark J Selby, John J Engelhardt, +4 authors, Alan J Korman.
Cancer Immunol Res, 2014 Apr 30; 1(1). PMID: 24777248
Highly Cited.
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.
Frederick Arce Vargas, Andrew J S Furness, +32 authors, Sergio A Quezada.
Cancer Cell, 2018 Mar 27; 33(4). PMID: 29576375    Free PMC article.
Highly Cited.
Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?
Fei Tang, Xuexiang Du, +2 authors, Yang Liu.
Cell Biosci, 2018 May 02; 8. PMID: 29713453    Free PMC article.
Robust enumeration of cell subsets from tissue expression profiles.
Aaron M Newman, Chih Long Liu, +6 authors, Ash A Alizadeh.
Nat Methods, 2015 Mar 31; 12(5). PMID: 25822800    Free PMC article.
Highly Cited.
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.
Michael J Overman, Sara Lonardi, +17 authors, Thierry André.
J Clin Oncol, 2018 Jan 23; 36(8). PMID: 29355075
Highly Cited.
Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice.
Xuexiang Du, Mingyue Liu, +8 authors, Pan Zheng.
Cell Res, 2018 Feb 22; 28(4). PMID: 29463898    Free PMC article.
Highly Cited.
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.
Eiichi Sato, Sara H Olson, +15 authors, Kunle Odunsi.
Proc Natl Acad Sci U S A, 2005 Dec 14; 102(51). PMID: 16344461    Free PMC article.
Highly Cited.
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
Tyler J Curiel, George Coukos, +18 authors, Weiping Zou.
Nat Med, 2004 Aug 24; 10(9). PMID: 15322536
Highly Cited.
Current knowledge of Ipilimumab and its use in treating non-small cell lung cancer.
Joseph A Pinto, Luis E Raez, Helena Oliveres, Christian C Rolfo.
Expert Opin Biol Ther, 2019 Apr 20; 19(6). PMID: 31002006
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
Matthew D Hellmann, Tudor-Eliade Ciuleanu, +21 authors, Luis Paz-Ares.
N Engl J Med, 2018 Apr 17; 378(22). PMID: 29658845    Free PMC article.
Highly Cited.
Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.
Ramaswamy Govindan, Aleksandra Szczesna, +19 authors, Martin Reck.
J Clin Oncol, 2017 Aug 31; 35(30). PMID: 28854067
Highly Cited.
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.
Rodabe N Amaria, Sangeetha M Reddy, +42 authors, Jennifer A Wargo.
Nat Med, 2018 Oct 10; 24(11). PMID: 30297909    Free PMC article.
Highly Cited.
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
Jedd D Wolchok, Vanna Chiarion-Sileni, +30 authors, James Larkin.
N Engl J Med, 2017 Sep 12; 377(14). PMID: 28889792    Free PMC article.
Highly Cited.
Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing.
Xinyi Guo, Yuanyuan Zhang, +16 authors, Zemin Zhang.
Nat Med, 2018 Jun 27; 24(7). PMID: 29942094
Highly Cited.
Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?
Matteo S Carlino, Georgina V Long.
Clin Cancer Res, 2016 Jun 25; 22(16). PMID: 27340279
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.
Eugene D Kwon, Charles G Drake, +24 authors, CA184-043 Investigators.
Lancet Oncol, 2014 May 17; 15(7). PMID: 24831977    Free PMC article.
Highly Cited.
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
Caroline Robert, Luc Thomas, +21 authors, Jedd D Wolchok.
N Engl J Med, 2011 Jun 07; 364(26). PMID: 21639810
Highly Cited.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma.
Xin Gao, David F McDermott.
Expert Opin Biol Ther, 2018 Aug 21; 18(9). PMID: 30124333    Free PMC article.
Underlying mechanisms and drug intervention strategies for the tumour microenvironment.
Haoze Li, Lihong Zhou, +2 authors, Qing Ji.
J Exp Clin Cancer Res, 2021 Mar 17; 40(1). PMID: 33722297    Free PMC article.
Immune checkpoints and immunotherapy in non-small cell lung cancer: Novel study progression, challenges and solutions.
Lin-Rui Ma, Jia-Xin Li, +5 authors, Pei-Yu Yan.
Oncol Lett, 2021 Oct 02; 22(5). PMID: 34594428    Free PMC article.
The new insight of treatment in Cholangiocarcinoma.
Yuhang Li, Yinghui Song, Sulai Liu.
J Cancer, 2022 Jan 25; 13(2). PMID: 35069894    Free PMC article.